Categories: News

New HBM+ report shares key insights on rapidly evolving drug landscape

TORONTO, Oct. 13, 2021 (GLOBE NEWSWIRE) — With the COVID-19 pandemic fundamentally changing health care delivery across the country, a new-look drug landscape is rapidly taking shape, sparked by the latest drug claim trends, the emergence of digital pharmacies, and a growing pipeline of ground-breaking therapies.

To make sense of the innovative approaches and extensive data, health benefits manager HBM+ is today releasing its second annual Drug Trends and Strategic Insights report, which presents drug claims and utilization data for HBM+ partner insurers and third party administers (TPAs), representing over two million claimants and almost $2 billion in annual adjudicated drug costs.

The report puts a spotlight on key trends tied to specialty drugs (particularly biologics and biosimilars) and the impact of new, costlier chronic disease therapies – all while presenting valuable cost management and health improvement solutions for plan sponsors and advisors. Equally, the report examines the impact of more and more Canadians turning to digital pharmacy options to obtain their medications due to lockdowns and distancing requirements.

Looking further ahead, the focus shifts to the pipeline of new drug therapies likely to have a significant effect on benefit plans this year and beyond, from gene therapies to a new treatment for Alzheimer’s disease to the ever-growing need for accessible mental health solutions.

“Our report provides an opportunity to step back and assess the challenges, trends, and realities resulting from the pandemic,” explains Charles Rosen, Managing Director at HBM+. “Building on these insights, HBM+ remains focused on serving our partners and their plan members in achieving sustainable health care solutions now and into the future.”

Click here to access the report.

For more information:

HBM+ Media Department
media@hbmplus.ca

About HBM+

HBM+ is more than a pharmacy benefits manager, it is a health benefits manager. With offices in Quebec and Ontario, HBM+ provides customized white-label solutions that support drug, dental and extended health benefits for group benefits carriers, third-party payors, and government organizations across Canada. HBM+ is built on a foundation of proven technology, seamless branding, innovative claim management and administration capabilities, collaborative provider management, and solid industry expertise. They recognize that each client is unique and requires a business solution tailored to their needs. hbmplus.ca

Staff

Recent Posts

Cheelcare Has a Record Month of Sales and Celebrates Milestone of 2,000 Companions Sold

Markham, Ontario--(Newsfile Corp. - December 8, 2025) - Cheelcare (TSXV: CHER), a Canadian innovator in…

43 minutes ago

SJTU International Gen Z Students Explore Shanghai’s Innovation Ecosystem

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- Shanghai Jiao Tong University's Antai Global Summer Program (AGSP)…

2 hours ago

Evotec Closes Sale of Just – Evotec Biologics’ Toulouse Site to Sandoz

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing…

5 hours ago

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

8 hours ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

8 hours ago